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Microscopic polyangiitis is a non-granulomatous, systematic and small-vessel vasculitis in
which necrotizing glomerulonephritis is very common and pulmonary capillaritis often
occurs. We report a patient with fever, fatigue and dry cough who initially had been
diagnosed as having pneumonia. A thoracic CTwas performed showing widespread multiple
nodular lesions, some with a central air-bronchogram and thickened bronchovascular
bundles and some connected to nodules. No cavitation or ground glass opacities were
observed. Fibreoptic bronchoscopy was normal and the cultures from the BAL were
negative. Additionally, during his stay in the hospital his hematocrit was gradually falling,
while the erythrocyte sedimentation rate increased. Urinanalysis revealed proteinuria and
active urinary sediment. p-ANCA was positive and renal biopsy revealed focal pauci-
immune necrotic glomerulonephritis. Pulmonary–renal syndrome was suspected and renal
biopsy was performed. The diagnosis of microscopic polyangiitis was established and the
patient began treatment with pulse intravenous methylprednisolone and cyclopho-
sphamide. After induction of remission, the patient received maintenance therapy.
Finally, an extensive review of the literature on microscopic polyangiitis is presented.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Microscopic polyangiitis (MPA) is deﬁned as systemic
necrotizing vasculitis with few or no immune deposits,
affecting small vessels (capillaries, arterioles or venules) in
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pulmonary capillaritis often occurs. Although MPA can
involve any organ, renal and pulmonary involvement
predominate.1–4 Pulmonary involvement can present from
ﬂeeting focal inﬁltrates to massive lung hemorrhage and
hemoptysis secondary to alveolar capillaritis.5Figure 2 Repeat chest radiograph a few days later shows
worsening of consolidation.Case history
This is a case of a 39-year-old male who was admitted to
hospital due to fever of unknown origin. He was an ex-
smoker (stopped 3 years ago) and his medical history is
unremarkable. Ten days back he was examined by his doctor
due to fever, fatigue and dry cough. He was diagnosed as
having pneumonia. He received cefuroxime axetil 500mg
bid for 7 days plus azithromycin once daily for 3 days with no
resolution of his symptomatology and he was referred to the
hospital. On examination, the patient was in no apparent
distress. He had normal breath sounds with normal blood
gases and his temperature was 38 1C. His laboratory studies
revealed white cell count: 13,900 (N:79, L:11.5, M:8.5,
E:0.6) hemoglobulin 13.7 g/dl. The erythrocyte sedimenta-
tion rate was elevated (72mm/h). Renal, liver function and
urinanalysis were normal. An arterial blood gas measure-
ment while the patient was breathing room air demon-
strated a PaO2 of 88mmHg, a PaCO2 41mmHg and
pH ¼ 7.39. Chest radiograph revealed a consolidation in
the right upper lobe (Figure 1).
The patient was admitted in our department and began
treatment with moxiﬂoxacin 400mg once daily. Samples
such as sputum and blood cultures, were obtained and
serology tests were conducted to rule out bacterial or viral
infection. A new radiograph showed an increase of the
consolidation (Figure 2). Due to nonresolving of the
shadowing on the X-ray, the treatment was switched toFigure 1 Chest radiograph on admission shows a consolidation
in the right upper lobe.ticarcillin/clavulanate potassium (5.2mg three times daily)
plus teicoplanine (400mg once daily).
Chest spiral computed tomography showed a few en-
larged lymph nodes in the paratracheal and carinal regions,
up to 1.5 cm in the short axis. Apart from the consolidation
in the right upper lobe, CT revealed multiple nodular
lesions, some with a central air-bronchogram, scattered in
all lobes, more prevalent in the upper and middle lung
ﬁelds. Thickened bronchovascular bundles were seen, some
connected to nodules (Figures 3A, 4A, 5A). No cavitation or
ground glass opacities were observed. Taking into account
the febrile patient and nonresolving ‘‘pneumonia’’, the
differential diagnosis was broadened widespread infections,
tuberculosis, whereas thickened bronchovascular bundles
connected with nodules and lymphadenopathy indicated
Wegener granulomatosis and lymphoma.
Fibreoptic bronchoscopy was normal and the cultures
from the BAL were negative. In addition, his hematocrit was
gradually falling (from 41% to 32%) while the erythrocyte
sedimentation rate was increasing (from 72 to 90mm/h). A
new urine analysis revealed proteinuria and active urinary
sediment. Pulmonary–renal syndrome was suspected and
tests for the detection of anti-GBM and antineutrophil
cytoplasmic antibody (ANCA) antibodies were performed.
Renal biopsy and a new sequential high-resolution computed
tomography of the thorax were performed.
HRCT showed extensive patchy areas of ground-glass
attenuation near the pre-existing lesions as well as in
previously normal areas, throughout both lungs. Resolution
of some nodules was observed. A halo of ground-glass
surrounding nodules was also seen, a CT sign known as the
halo sign, strongly indicative of hemorrhagic inﬁltration
(Figures 3B, 4B, 5B). The rapidity of nodules resolution
coupled with the appearance of ground-glass and halo-sign,
and in the absence of cavitary lesions that would include
Wegener’s granulomatosis, indicated intrapulmonary hemor-
rhage and capillaritis compatible with MPA, in the proper
clinical settings.
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Figure 3 (A) Spiral ct obtained at presentation shows air-space
consolidation in the right upper lobe and a nodule with air-
bronchogram in the left upper lobe. (B) Follow-up sequential
HRCT reveals development of extensive areas of ground-glass
attenuation as well as thickening of bronchovascular bundles
(arrow).
Figure 4 (A) Initial spiral CT at the level of the bronchus
intermedius, shows multiple nodules in both lungs connected to
thickened bronchovascular bundles. (B) Follow-up HRCT at the
same level shows resolution of some nodular opacities in the
right lung and patchy ground-glass opacities in both lung ﬁelds.
Newly developed ground-glass areas surround nodules in the left
lung, a CT sign strongly indicative of hemorrhagic inﬁltration
(arrows).
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pauci-immune necrotic glomerulonephritis. Thus, the diag-
nosis of MPA was established and the patient began the
treatment with pulse intravenous 1000mg methylpredniso-
lone for 3 days, followed by pulse intravenous cyclopho-
sphamide 0.75mg/m2. The dose of the steroids was
gradually tapered to 10mg/day of prednisolone and the
patient had in total received six cycles of intravenous
cyclophosphamide. Remission was achieved and during his
last reevaluation, p-ANCA were negative and HRCT of the
thorax had no signs of activity.
After induction of remission, the patient received main-
tenance therapy with 10mg/day plus azathioprine 150mg/
day (Table 2).Discussion
The primary systemic vasculitides are heterogeneous, multi-
system disorders characterized by inﬂammation and necrosis
of small and medium blood vessels. These disorders are also
known as the ANCA-associated vasculitides and include
Wegener’s granulomatosis (WG), Churg–Strauss syndrome
(CSS) and microscopic pulmonary angiitis (MPA). In theseconditions, lung involvement predominates in 50–95% of
affected patients. Their etiology is unknown.
Serum ANCA are involved in the pathogenesis of these
conditions and has been recognized as a useful marker for
diagnosing small vessels vasculitis.1,6,7 ANCA include three
categories of antibodies based on their pattern of indirect
immunoﬂuorescence on ethanol-ﬁxed neutrophils: a diffuse
cytoplasmic granular pattern, a perinuclear pattern, and an
atypical pattern.8 Two staining patterns are known, peri-
nuclear (p-ANCA) and cytoplasmic (c-ANCA). The major
target antigen of p-ANCA associated with vasculitis is
myeloperoxidase (MPO), while that of c-ANCA is proteinase
3 (PR3). MPO-ANCA is related to MPA, where it has been
reported in 15–45% of the patients9–11 and PR3-ANCA is the
marker antibody in WG.
The most common presenting clinical symptoms of MPA
are fever, weight loss, malaise, followed by myalgias and
arthralgias. Many patients describe a ‘‘ﬂu-like’’ syndrome
early in the course of their disease. Other involvement
include hemoptysis, hematuria, proteinuria, abdominal
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Figure 5 (A) Initial spiral CT at the level of basal segments of
the lower lobes shows a rather smooth nodule in the right lower
lobe. (B) Follow-up HRCT shows a halo of ground-glass
surrounding the nodule and neighboring peripheral bronchovas-
cular bundle thickening (arrow).
K.M. Antoniou et al.172pain, gastrointestinal bleeding secondary to mucosal vascu-
litis, peripheral neuropathy, arthritis, myositis and sinusi-
tis.1,11,12
MPA can cause a variety of pulmonary abnormalities.
Diffuse alveolar hemorrhage (DAH) with or without pulmon-
ary capillaritis is the main pulmonary manifestation.9,13,14 A
small-vessel vasculitis causing DAH is reported in 10–30% of
patients with MPA.9 Pulmonary interstitial ﬁbrosis can also
be an initial manifestation of MPA and seems to be
associated with a poorer prognosis.15 Other pulmonary
presentations of MPA are nonspeciﬁc interstitial pneumonia,pulmonary aneurysm and alveolar hemorrhage, pleural
effusion, pulmonary edema and diffuse panbronchioli-
tis.16–18
Chest radiographic abnormalities consist of patchy,
bilateral airspace opacities ranging in intensity from vague
ground-glass opacity to extensive intense consolidation
caused by hemorrhagic ﬁlling of the airspaces. The most
commonly referred CT ﬁndings are ground-glass attenuation
followed by consolidation, thickening of bronchovascular
bundles, interlobular septal thickening and nodules ranging
from centrilobular micronodules sized a few mm to over
1 cm. Rarer manifestations are honeycombing and bronch-
iectasis.13–15,19–21
CT–pathologic correlation20 has shown that the extent of
ground-glass attenuation corresponds to that of alveolar
hemorrhage, interstitial chronic inﬂammation in the alveo-
lar septa and vasculitis in the small-sized arteries, the
consolidation corresponds mostly to diffuse alveolar hemor-
rhage and the thickening of bronchovascular bundles
corresponds to the inﬁltration of lymphocytes and mild
ﬁbrosis along the bronchovascular bundles.
The zonal predominance is not characteristic and a
random distribution is almost equal to an upper or lower
zones predominance.13,14,20 Although spiral and high-resolu-
tion CT have a higher sensitivity than chest radiography for
demonstrating the extent and nature of parenchymal
lesions, often the CT features are not speciﬁc, as was the
case in the onset CT of our patient. However, during the
evolution of the disease, new CT ﬁndings evolved, strongly
suggestive of intraparenchymal hemorrhage and possible
capillaritis. The rapidity of clearing of small nodules,
consolidations representing absorption of intra-alveolar
blood and the appearance of ground-glass attenuation areas
often surrounding nodules creating the known halo sign are
all features of pulmonary hemorrhage.13,19,20 Nevertheless,
a high conﬁdent level diagnosis can be reached only in the
proper clinical context.
Routine laboratory tests are not speciﬁc. Urinanalysis
reveals dysmorphic red cells of glomerular origin, red-cell
casts and other cellular and granular casts. Proteinuria is
always present, but rarely in the range of nephritic
syndrome.22
In contrast to WG, most ANCA-positive MPA patients have
MPO-ANCA, with a minority having PR3-ANCA. We must
underline the fact that according to the International
Consensus Statement on Testing and Reporting of antineu-
trophil cytoplasmic antibodies, combining indirect immuno-
ﬂuorescence assays and enzyme immunoassays (ELISAs) is
more accurate than either assay alone.23 Not everybody
with PR3-c-ANCA or MPO-p-ANCA has active vasculitis.
Alternatively, not every ANCA vasculitis patient relapses
when the ANCAs recur or persist. This suggests that,
pathogenetically, a sufﬁcient number of ANCAs need to
persist long enough, before an exposure of the patient to
cofactors that, via subsequent neutrophil and monocyte
priming, leads to interaction between ANCAs and their
target antigen on the effector cell surface. This interaction,
in turn, triggers the cascade, leading to endothelial cell
damage.
Bronchoscopy should be performed to rule out infection
and to evaluate the presence of the DAH. Bronchoalveolar
lavage ﬂuid in MPA patients with alveolar hemorrhage is
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throcytes and hemosiderin-laden macrophages.24
The gold standard for the diagnosis is performing biopsy of
the involved organs that reveals necrotizing crescentic
glomerulonephritis and necrotizing vasculitis of arterioles,
capillaries, and venules with few immune deposits. In
addition to the precise diagnosis, evaluation of the extent
of organ involvement is also important because it deter-
mines which therapeutic strategy should be chosen. The
Birmingham Vasculitis Activity Index (BVAS)25 is employed
for the evaluation of the activity of vasculitis, and the
Vasculitis Damage Index (VDI)2 for the analysis of organ
damage. The Japanese Research Group of Intractable
Vasculitis, MHLW was established in 1998 and diagnostic
criteria for MPA are listed in Table 1.
The distinction between WG and MPA is another important
issue chieﬂy because of differential tendencies to ﬂare.
Although both diseases may ﬂare after the achievement of
remission, WG is substantially more likely to relapse.
Because PR3-ANCA or MPO-ANCA may occur in both WG
and MPA, these diseases cannot be distinguished on the basis
of ANCA speciﬁcity. WG is differentiated by the presence of
necrotizing granulomatous inﬂammation.2
Renal survival and overall mortality in patients with MPA
are found to depend on immunosuppressive treatment, type
of organ involvement, presence of ANCA, older age,
maximum creatinine in the ﬁrst month, gastrointestinal
involvement and male gender.26 The 5-year survival variesTable 1 Diagnostic criteria for microscopic polyangii-
tis.
1. Symptoms
(1) Rapidly progressive glomerulonephritis
(2) Pulmonary hemorrhage
(3) Other organ symptoms:
Purpura, subcutaneous hemorrhage, gastrointestinal
bleeding and mononeuritis multiplex
2. Histological ﬁndings
(1) Necrotizing vasculitis of arterioles, capillaries, and
venules, and perivascular inﬁltration of inﬂammatory
cells
3. Laboratory ﬁndings
(1) Positive MPO-ANCA
(2) Positive CRP
(3) Proteinuria, hematuria, elevation of BUN and serum
creatinine
Diagnosis
1. Deﬁnite MPA
(1) Positive for two or more of the symptoms, and
positive histological ﬁndings
(2) Positive for two or more of the symptoms including
the symptoms (1) and (2), and positive MPO-ANCA
2. Probable MPA
(1) Positive for three of the symptoms
(2) Positive for one of the symptoms, and positive MPO-
ANCA
From the Research Group of Intractable Vasculitis, MHLW of
Japan (2002).2from 45% to 76% in different studies and the relapse rate is
8% in the ﬁrst 2 years.26
Treatment for ANCA-associated vasculitides is now well
deﬁned, but must be adjusted for each patient according to
the type of vasculitis, its precise form (e.g., limited versus
systemic Wegener’s granulomatosis) and severity, and
patients’ characteristics such as age and renal function.
The therapeutic decision must also take into account the
risk of adverse events inherent to each treatment. Im-
munosuppression is the cornerstone of treatment in MPA.
The induction therapy in generalized MPA-severe form
(multi-organ involvement, a renal–pulmonary type and
rapidly progressive glomerulonephritis (RPGN)) consists of
oral prednisolone (0.6–1mg/kg/day) plus oral cyclopho-
sphamide (0.5–2mg/kg/day). Intravenous methylpredniso-
lone (0.5–1.0 g/day for 3 days) can be considered. As the life
threatening features subside, the dose can then be reduced
to 1mg/kg prednisolone (or equivalent) daily for the ﬁrst
month, tapered over the next 3–4 months. Instead of oral
administration, intravenous cyclophosphamide (0.5–0.75 g/m2,
monthly) can also be considered.23,27 For the RPGN type,
anti-coagulation therapy (heparin at 10,000 units/day
or low-molecular heparin at 5000 units/day) and anti-
platelet therapy (dipyridamole at 300mg/day) are also
employed.28–30 In patients with impaired renal func-
tion (serum creatinine level 41.8mg/dl) or those more
than 60 years old, the dose of cyclophosphamide should be
reduced to 75–50%. Severe disease deﬁned by major renal
impairment (serum creatinine 45.7mg/dl) was recently
suggested to be treated with corticosteroids and cyclopho-
sphamide coupled with plasma exchange at least for the ﬁrst
week to increase the likelihood for renal function restora-
tion.31,32 There are reports suggesting that extracorporeal
membrane oxygenation and activated human factor VII may
be beneﬁcial in some critically ill patients with DAH33–35
(Table 2).
With this treatment remission is evaluated by approxi-
mately 85% and in general can be achieved within 6
months.36,37 Patients who have attained remission receive
maintenance therapy for additional 1 year.38 The main-
tenance therapy includes prednisolone (5–10mg/day) and in
most cases oral cyclophospamide or azathioprine (25–75mg/
day). Relapse will occur in 11–57% of patients in remission.
Female, black race, severe kidney disease, upper airway
disease and anti-Pr3 serum antibodies are shown to be risk
factors for resistance to initial treatment.38Table 2 Pulmonary function tests of patient at pre-
sentation, after pulse therapy and under maintenance
therapy.
At
presentation
After
pulse
6mo with
AZA
FVC (%pred) 108 105 102
FEV1 (%pred) 105 104 101
FEV1/FVC 80.5 94 81.5
TLCO (%pred) 83.6 87.6 89
TLCO/VA
(%pred)
94.8 95.5 94
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depletion agents, mycophenolate mofetil, leﬂunomide and
antithymocyte globulin.39–50 Most of these agents are
associated with strong adverse effects. So in the absence
of further data, these experimental treatments should not
be used.
In conclusion, the diagnosis of vasculitis is often delayed
because the clinical manifestation can be mimicked by a
number of other disorders. Establishing the diagnosis of
microscopic polyangiits is a particularly difﬁcult task,
especially in patients presenting with pulmonary inﬁltrates
and fever, having no prior disease label and without
hemoptysis—a clinical scenario resembling ‘‘pneumonia’’.
Renal and pulmonary symptoms are characteristic in micro-
scopic polyangiitis (MPA), and interstitial pneumonitis and
pulmonary hemorrhage are common. The treating physician
should always bear in mind that pulmonary–renal syndrome
at ﬁrst presentation may not only mimic pneumonia, but in
certain cases could be triggered by pneumonia.References
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